Induced pluripotent stem cells: Advances to applications

Timothy J. Nelson, Almudena Martinez-Fernandez, Satsuki Yamada, Yasuhiro Ikeda, Carmen Perez-Terzic, Andre Terzic

Research output: Contribution to journalReview article

29 Scopus citations

Abstract

Induced pluripotent stem cell (iPS) technology has enriched the armamentarium of regenerative medicine by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue. Through nuclear reprogramming, patient-specific iPS cells have been derived and validated. Optimizing iPS-based methodology will ensure robust applications across discovery science, offering opportunities for the development of personalized diagnostics and targeted therapeutics. Here, we highlight the process of nuclear reprogramming of somatic tissues that, when forced to ectopically express stemness factors, are converted into bona fide pluripotent stem cells. Bioengineered stem cells acquire the genuine ability to generate replacement tissues for a wide-spectrum of diseased conditions, and have so far demonstrated therapeutic benefit upon transplantation in model systems of sickle cell anemia, Parkinson's disease, hemophilia A, and ischemic heart disease. The field of regenerative medicine is therefore primed to adopt and incorporate iPS cell-based advancements as a next generation stem cell platforms.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalStem Cells and Cloning: Advances and Applications
Volume3
Issue number1
StatePublished - Nov 1 2010

Keywords

  • Individualized medicine
  • Regenerative medicine
  • Stem cell therapy
  • iPS

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Cell Biology

Fingerprint Dive into the research topics of 'Induced pluripotent stem cells: Advances to applications'. Together they form a unique fingerprint.

  • Cite this